title: Human mesenchymal stromal cells ameliorate the phenotype of SOD1-G93A ALS mice.
abstract: BACKGROUND
  Amyotrophic lateral sclerosis (ALS) is a progressive, lethal, neurodegenerative disease, currently without any effective therapy. Multiple advantages make mesenchymal stromal cells (MSC) a good candidate for cellular therapy in many intractable diseases such as stroke and brain injury. Until now, no irrefutable evidence exists regarding the outcome of MSC transplantation in the mouse model of ALS. The present study was designed to investigate the therapeutic potential of human MSC (hMSC) in the mouse model of ALS (SOD1-G93A mice).
  
  
  METHODS
  hMSC were isolated from iliac crest aspirates from healthy donors and kept in cell cultures. hMSC of the fifth passage were delivered intravenously into irradiated pre-symptomatic SOD1-G93A mice. Therapeutic effects were analyzed by survival analysis, rotarod test, motor neuron count in spinal cord and electrophysiology. The engraftment and in vivo differentiation of hMSC were examined in the brain and spinal cord of hMSC-transplanted mice.
  
  
  RESULTS
  After intravenous injection into irradiated pre-symptomatic SOD1-G93A mice, hMSC survived more than 20 weeks in recipient mice, migrated into the parenchyma of brain and spinal cord and showed neuroglia differentiation. Moreover, hMSC-transplanted mice showed significantly delayed disease onset (14 days), increased lifespan (18 days) and delayed disease progression compared with untreated mice.
  
  
  CONCLUSIONS
  Our data document the positive effects of hMSC transplantation in the mouse model of ALS. It may signify the potential use of hMSC in treatment of ALS.
authors.affiliation: Department of Neurology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, PR China.
authors.forename: C-P
authors.initials: CP
authors.lastname: Zhao
authors.forename: C
authors.initials: C
authors.lastname: Zhang
authors.forename: S-N
authors.initials: SN
authors.lastname: Zhou
authors.forename: Y-M
authors.initials: YM
authors.lastname: Xie
authors.forename: Y-H
authors.initials: YH
authors.lastname: Wang
authors.forename: H
authors.initials: H
authors.lastname: Huang
authors.forename: Y-C
authors.initials: YC
authors.lastname: Shang
authors.forename: W-Y
authors.initials: WY
authors.lastname: Li
authors.forename: C
authors.initials: C
authors.lastname: Zhou
authors.forename: M-J
authors.initials: MJ
authors.lastname: Yu
authors.forename: S-W
authors.initials: SW
authors.lastname: Feng
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D000818:Animals; D001921:Brain / Q000166:cytology / Q000503:physiopathology; D002454:Cell Differentiation / Q000502:physiology; D002470:Cell Survival / Q000502:physiology; D002478:Cells, Cultured; D004195:Disease Models, Animal; D006085:Graft Survival / Q000502:physiology; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D051379:Mice; D008822:Mice, Transgenic; D009046:Motor Neurons / Q000166:cytology / Q000201:enzymology; D009457:Neuroglia / Q000166:cytology / Q000502:physiology; D020127:Recovery of Function / Q000502:physiology; D018570:Risk Assessment; D013116:Spinal Cord / Q000166:cytology / Q000503:physiopathology; D017154:Stromal Cells / Q000502:physiology* / Q000637:transplantation*; D013482:Superoxide Dismutase / Q000235:genetics*; D014183:Transplantation, Heterologous; D016896:Treatment Outcome